Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-2608 plus fulvestrant vs capivasertib plus fulvestrant in PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor
2025-523083-21-00Phase 3Authorised
- Sponsor
- Relay Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of zovegalisib in breast cancer (2 arms), sponsored by Relay Therapeutics. Planned start Dec 2025; status: authorised.
02
Drugs
zovegalisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-523083-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523083-21-00.